NAPLEX (North American Pharmacist Licensure Examination) Practice Exam

Disable ads (and more) with a membership for a one time $2.99 payment

Study for the NAPLEX exam with a comprehensive quiz featuring multiple-choice questions and in-depth explanations. Build your pharmacological knowledge and increase your chances of passing the pharmacist licensure examination!

Each practice test/flash card set has 50 randomly selected questions from a bank of over 500. You'll get a new set of questions each time!

Practice this question and more.

What is a characteristic effect of Degarelix and Relugolix?

Increased risk of osteoporosis and tumor flare
Osteoporosis risk, no tumor flare
Immediate increase in testosterone
High risk of gynecomastia

The correct answer is: Osteoporosis risk, no tumor flare

Both Degarelix and Relugolix are gonadotropin-releasing hormone (GnRH) antagonists, which means they inhibit the production of sex hormones such as testosterone. This results in a decreased risk of osteoporosis, as seen in option B. Option A is incorrect because it includes an incorrect characteristic effect, tumor flare, which is actually a possible outcome when starting GnRH agonist treatment, not antagonist treatment. Option C is incorrect because it suggests an immediate increase in testosterone, which is not a characteristic effect of these drugs. Option D is also incorrect because gynecomastia is not a known side effect of Degarelix and Relugolix. Overall, the correct answer, option B, is the only one that accurately describes the characteristic effect of these drugs.